Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diamine containing VLA-4 antagonists.

P C Astles1, N V Harris, A D Morley

  • 1Aventis Pharma Ltd, Dagenham Research Centre, Dagenham, RM10 7XS, Essex, UK.

Bioorganic & Medicinal Chemistry
|August 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of non-tuberculous mycobacterial cervicofacial lymphadenitis in children: critical appraisal of the literature.

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·2009
Same author

A review of sinonasal outcome scoring systems - which is best?

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·2006
Same author

Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands.

Current drug targets. CNS and neurological disorders·2003
Same author

Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.

Journal of medicinal chemistry·2000
Same author

Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.

Journal of medicinal chemistry·1998
Same author

Selective endothelin A receptor antagonists. 4. Discovery and structure-activity relationships of stilbene acid and alcohol derivatives.

Journal of medicinal chemistry·1998
Same journal

Transport specificity of FpvA and FpvB for pyoverdine-antibiotic conjugates in Pseudomonas aeruginosa.

Bioorganic & medicinal chemistry·2026
Same journal

Design and engineering of μO-conotoxin MfVIA mutants to enhance Na<sub>V</sub>1.8 inhibition and analgesic efficacy in inflammatory pain.

Bioorganic & medicinal chemistry·2026
Same journal

Recent advances in Camptothecin-derived antibody-drug conjugates.

Bioorganic & medicinal chemistry·2026
Same journal

CDK4/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance.

Bioorganic & medicinal chemistry·2026
Same journal

Coumarin-sulfonamide hybrids as PKM2 activators induce metabolic reprogramming and suppress ovarian cancer cell growth.

Bioorganic & medicinal chemistry·2026
Same journal

Recent advances in the development of small-molecule drugs based on covalent reversible inhibitors.

Bioorganic & medicinal chemistry·2026
See all related articles

Researchers designed novel VLA-4 antagonists for potential therapeutic use. The developed compounds show high potency in inhibiting VLA-4, offering a promising foundation for further drug development programs.

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Immunology

Background:

  • Integrin alpha4beta1 (VLA-4) is a key mediator of cell adhesion implicated in inflammatory diseases.
  • Targeting VLA-4 offers a therapeutic strategy for conditions involving leukocyte trafficking.

Purpose of the Study:

  • To design and synthesize a novel library of potential VLA-4 antagonists.
  • To identify potent VLA-4 inhibitors and establish structure-activity relationships (SAR).
  • To provide a starting point for lead optimization in developing new therapeutics.

Main Methods:

  • Design of compounds based on a proposed pharmacophoric model.
  • Synthesis of a chemical library.
  • In vitro assays to determine inhibitory potency (IC50) against VLA-4 mediated fibronectin binding to RAMOS cells.

Related Experiment Videos

Main Results:

  • A library of potential VLA-4 antagonists was successfully synthesized.
  • Compounds with submicromolar potency were identified.
  • Structure-activity relationships were elucidated across the synthesized library.
  • Further derivatization yielded compounds with IC50 values below 10 nmol.

Conclusions:

  • The study successfully identified potent VLA-4 antagonists.
  • The developed compounds represent an excellent starting point for lead optimization.
  • This work contributes to the development of novel therapeutics targeting VLA-4.